Radioimmunotherapy deemed safe and effective for lymphoma patients

A new treatment option for patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas has been determined safe and feasible by researchers exploring the potential of a low energy beta-emitter radiopharmaceutical. According to data published in the July issue of The Journal of Nuclear Medicine, the use of 177Lu-DOTA-rituximab as a radioimmunotherapy results in a high rate of tumor response while using less radiation than current therapies.

"Twelve years ago, when we started the study, it seemed that radioimmunotherapy could be a highly interesting tool that was both easy for clinicians to use and well-tolerated in patients. It also was clear that the use of iodine radionuclides was inconvenient for handling and not practical for patients because of the need for prolonged in hospital days due to radiation protection measures," said Andreas Lohri, MD, lead author of the study "Radioimmunotherapy with 177Lu-DOTA-Rituximab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas." "Although 90Y ibritumomab tiuxetan—Zevalin—was introduced shortly after we started the study, we felt it was important to do clinical experiments with other radionuclides."

The prospective study included 31 patients with histologically confirmed relapsed or refractory CD20-positive B-cell lymphoma. All patients received an initial dose of 740 MBq/m2 body surface area of 177Lu-DOTA rituximab.. Doses were increased in steps of 185 MBq/m2 over a maximum of seven doses. Hematologic and nonhematologic toxicity was measured weekly up to week 10 or until recovery from the lowest level of blood cell count. Imaging with whole body computed tomography (CT) and 18F-FDG positron emission tomography (PET) or 18F-FDG PET/CT was conducted at baseline and at 8-12 weeks.

The maximum tolerated dose using 177Lu-DOTA rituximab was 1,665 MBq/m2. Toxicity was mainly hematologic, with thrombocytopenia and leukopenia noted as the dose-limiting toxicities, and nonhematologic toxicity was minor. Clinical responses occurred at all dose levels for patients with follicular (82 percent overall response rate) and mantle cell (21 percent response rate) lymphomas. With a median follow-up of almost seven years, the estimated median time of survival after radioimmunotherapy was four years.

"With 177Lu-DOTA Rituximab we can essentially do CD20 imaging," said Lohri. "At the moment, this may be academically interesting and could potentially be used in daily practice if compared to all forms of current PET imaging."

More information: "Radioimmunotherapy with 177Lu-DOTA-Rituxmab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas" The Journal of Nuclear Medicine, 2013.

Related Stories

A new treatment option may soon be available for children with neuroblastoma according to research published in the July issue of The Journal of Nuclear Medicine. The study tested the principle that combined positron emissi ...

Outcomes can be bleak for non-Hodgkin lymphoma (NHL), a cancer that develops in the white blood cells of the immune system. Accurate estimation of radiation absorbed dose in radioimmunotherapy (RIT) based on state-of-the-art ...

A new patient protocol for aggressive and recurrent lymphoma that combines intensive chemotherapy and radioimmunotherapy (RIT) may become the most powerful cancer-killing therapy available, with the hope that patients' lymphoma ...

New research published in the January issue of The Journal of Nuclear Medicine shows that 18F-fludeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) imaging offers significant prognostic strati ...

After five years of follow-up, a majority of asymptomatic, benign thyroid nodules exhibited no significant change in size, or actually decreased in size, and diagnoses of thyroid cancer were rare, according to a study in ...

Tumor recurrence following a period of remission is the main cause of death in cancer. The ability of cancer cells to remain dormant during and following therapy, only to be reactivated at a later time, frequently ...

Extra virgin olive oil (EVOO), long-known for its heart health benefits, has now been identified for its rapid destruction of cancer cells. While scientists have proven that the oleocanthal compound found ...

A magnetic resonance spectroscopy (MRS) technique that monitors biochemical changes in tissue could improve the management of women at risk of breast cancer, according to a new study published online in the ...

Despite sharp increases in spending on cancer treatment, cancer mortality rates in the United States have decreased only modestly since 1970, Samir Soneji, PhD of Dartmouth's Norris Cotton Cancer Center and The Dartmouth ...

User comments

Please sign in to add a comment.
Registration is free, and takes less than a minute.
Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.